肺癌早期诊断标志物研究进展  

Advances in biomarkers researches for early diagnosis of lung cancer

作　　者：郑泽茂 王继鹏[1] ZHENG Zemao;WANG Jipeng(Department of Respiratory and Critical Care Medicine,Huai an First Hospital Affiliated to Nanjing Medical University,Huai an 223300,Jiangsu,China)

机构地区：[1]南京医科大学附属淮安第一医院呼吸与危重症医学科,江苏淮安223300

出　　处：《中南医学科学杂志》2025年第1期185-188,共4页Medical Science Journal of Central South China

基　　金：江苏省科学技术协会调研课题(JSKXKT2023029)。

摘　　要：肺癌是一种侵袭性肿瘤,其死亡率与晚期诊断密切相关。早期诊断可有效提高治愈率,减轻社会疾病负担。当前胸部低剂量计算机断层扫描是主流的筛查方式,但存在费用高、假阳性等问题,采用非侵入性生物标志物筛查肺癌是当前临床上的迫切需求。本文总结了目前有前途的候选新型肿瘤生物标志物的发展现状,如血液蛋白谱、自身抗体、miRNA、循环肿瘤DNA、循环肿瘤细胞及呼出气体中的挥发性有机化合物,并对未来发展进行了前景预测,以期为肺癌早期诊断的发展提供参考。Lung cancer is an aggressive tumor whose mortality is closely related to late diagnosis.Early diagnosis can effectively improve the cure rate and reduce the burden of disease in society.Currently,low-dose chest computed tomography is the mainstream screening method,but there are some problems such as high cost and false positives,and the lung cancer screening of non-invasive biomarkers is an urgent clinical need.This review summarizes the current status of promising candidate biomarkers,such as blood protein profiles,autoantibodies,miRNA,circulating tumor DNA,circulating tumor cells,and volatile organic compounds in exhaled gas.Additionally,the prospect of future development is predicted to provide reference for the development of early diagnosis of lung cancer.

关 键 词：肺癌 生物标志物 筛查 早期诊断 

分 类 号：R734.2[医药卫生—肿瘤]